Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 6, 2015, Pages 717-723

  Loricera, Javier ^a   Blanco, Ricardo ^a   Hernández, José L ^a   Castañeda, Santos ^b   Mera, Antonio ^c   Pérez Pampín, Eva ^c   Peiró, Enriqueta ^a   Humbría, Alicia ^b   Calvo Alén, Jaime ^d   Aurrecoechea, Elena ^d   Narváez, Javier ^e   Sánchez Andrade, Amalia ^f   Vela, Paloma ^g   Díez, Elvira ^h   Mata, Cristina ⁱ   Lluch, Pau ^j   Moll, Concepción ^j   Hernández, Íñigo ^k   Calvo Río, Vanesa ^a   Ortiz Sanjuán, Francisco ^a   González Vela, Carmen ^a   Pina, Trinitario ^a   González Gay, Miguel Á ^a   more..

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d HOSPITAL SIERRALLANA   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f HOSPITAL UNIVERSITARIO LUCUS AUGUSTI   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^h Complejo Asistencial Universitario de León   (Spain)

ⁱ HOSPITAL DE LAREDO   (Spain)

^j Hospital Mateu Orfila   (Spain)

^k UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

more..

Author keywords

Biological therapy; Giant cell arteritis; Large vessel vasculitis; Tocilizumab

Indexed keywords

C REACTIVE PROTEIN; MONOCLONAL ANTIBODY; TOCILIZUMAB;

AGED; CLINICAL TRIAL; COMPLICATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GIANT CELL ARTERITIS; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; MULTICENTER STUDY; POLYMYALGIA RHEUMATICA; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FEMALE; GIANT CELL ARTERITIS; HUMANS; MALE; MIDDLE AGED; POLYMYALGIA RHEUMATICA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84922963062     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.12.005     Document Type: Article

References (50)

1. Salvarani C., Cantini F., Boiardi L., Hunder G.G. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002, 347:261-271.
2. Gonzalez-Gay M.A., Vázquez-Rodriguez T.R., Lopez-Diaz M.J., Miranda-Filloy J.A., Gonzalez-Juanatey C., Martin J., et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009, 61:1454-1461.
3. González-Gay M.A., García-Porrúa C., Llorca J., Hajeer A.H., Brañas F., Dababneh A., et al. Visual manifestations of giant cell arteritis: trends and clinical spectrum in 161 patients. Medicine (Baltimore) 2000, 79:283-292.
4. Gornik H.L., Creager M.A. Aortitis. Circulation 2008, 117:3039-3051.
5. Gonzalez-Gay M.A., Garcia-Porrua C., Piñeiro A., Pego-Reigosa R., Llorca J., Hunder Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine (Baltimore) 2004, 83:335-341.
6. Evans J.M., O'Fallon W.M., Hunder G.G. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis: a population-based study. Ann Intern Med 1995, 122:502-507.
7. Loricera J., Blanco R., Hernández J., Carril J., Martínez-Rodríguez I., Canga A., et al. Non-infectious aortitis: a report of 32 cases from a single tertiary centre in a 4-year period and literature review. Clin Exp Rheumatol 2015, [In press].
8. Jones S.A. Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 2005, 175:3463-3468.
9. Blain H., Abdelmouttaleb I., Belmin J., Blain A., Floquet J., Guéant J.L., et al. Arterial wall production of cytokines in giant cell arteritis: results of a pilot study using human temporal artery cultures. J Gerontol A Biol Sci Med Sci 2002, 57:241-245.
10. Cid M.C., Campo E., Ercilla G., Palacin A., Vilaseca J., Villalta J., et al. Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunologic activation markers in temporal arteritis: influence of corticosteroid treatment. Arthritis Rheum 1989, 32:884-893.
11. Proven A., Gabriel S.E., Orces C., O'Fallon W.M., Hunder G.G. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003, 49:703-708.
12. Martinez-Lado L., Calviño-Díaz C., Piñeiro A., Dierssen T., Vazquez-Rodriguez T.R., Miranda-Filloy J.A., et al. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore) 2011, 90:186-193.
13. Hoffman G.S., Cid M.C., Hellmann D.B., Guillevin L., Stone J.H., Schousboe J., et al. A multicenter, randomized, double blind, placebo-controlled trial of adjuvant MTX treatment for giant cell arteritis. Arthritis Rheum 2002, 46:1309-1318.
14. Jover J.A., Hernández-García C., Morado I.C., Vargas E., Bañares A., Fernández-Gutiérrez B., et al. Combined treatment of giant cell arteritis with MTX and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001, 134:106-114.
15. Mahr A.D., Jover J.A., Spiera R.F., Hernández-García C., Fernández-Gutiérrez B., Lavalley M.P., et al. Adjunctive MTX for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007, 56:2789-2797.
16. Spiera R.F., Mitnick H.J., Kupersmith M., Richmond M., Spiera H., Peterson M.G., et al. A prospective, double-blind, randomized, placebo controlled trial of MTX in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 2001, 19:495-501.
17. De Silva M., Hazleman B.L. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986, 45:136-138.
18. Henes J.C., Mueller M., Pfannenberg C., Kanz L., Koetter I. Cyclophosphamide for large vessel vasculitis: assessment of response by PET/CT. Clin Exp Rheumatol 2011, 29:S43-S48.
19. Hoffman G.S., Cid M.C., Rendt-Zagar K.E., Merkel P.A., Weyand C.M., Stone J.H., et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007, 146:621-630.
20. Seror R., Baron G., Hachulla E., Debandt M., Larroche C., Puéchal X., et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomized controlled trial. Ann Rheum Dis 2014, 73:2074-2078.
21. Weyand C.M., Goronzy J.J. Medium- and large-vessel vasculitis. N Engl J Med 2003, 349:160-169.
22. Dasgupta B., Panayi G.S. Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 1990, 29:456-458.
23. Emilie D., Liozon E., Crevon M.C., Lavignac C., Portier A., Liozon F., et al. Production of interleukin 6 by granulomas of giant cell arteritis. Hum Immunol 1994, 39:17-24.
24. Unizony S., Stone J.H., Stone J.R. New treatment strategies in large-vessel vasculitis. Curr Opin Rheumatol 2013, 25:3-9.
25. Naka T., Nishimoto N., Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002, 4(Suppl. 3):S233-S242.
26. Loricera J., Blanco R., Castañeda S., Humbría A., Ortego-Centeno N., Narváez J., et al. Tocilizumab in refractory aortitis: study on 16 patients and literature review. Clin Exp Rheumatol 2014, 32(Suppl. 82):79-89.
27. Pazzola G., Padovano I., Boiardi L., Versari A., Pipitone N., Catanoso M., et al. Tocilizumab in glucocorticoid-naïve large-vessel vasculitis. Case report. Clin Exp Rheumatol 2013, 31(Suppl. 75):S59-S61.
28. Beyer C., Axmann R., Sahinbegovic E., Distler J.H.., Manger B., Schett G., et al. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis 2011, 70:1874-1875.
29. Christidis D., Jain S., Das Gupta B. Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement. BMJ Case Rep 2011, 10.1136/bcr.04.2011.4135.
30. Salvarani C., Magnani L., Catanoso M., Pipitone N., Versari A., Dardani L., et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 2012, 51:151-156.
31. Seitz M., Reichenbach S., Bonel H.M., et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade: a case series. Swiss Med Wkly 2011, 141:w13156.
32. Unizony S., Arias-Urdaneta L., Mioslavsky E., Arvikar S., Khosroshahi A., Keroack B., et al. Tocilizumab for the treatment of large- vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatic. Arthritis Care Res (Hoboken) 2012, 64:1720-1729.
33. Sciascia S., Rossi D., Roccatello D. Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis. J Rheumatol 2011, 38:2080-2081.
34. Hunder G.G., Bloch D.A., Michel B.A., Stevens M.B., Arend W.P., Calabrese L.H., et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990, 33:1122-1128.
35. Chuang T.-Y., Hunder G.G., Ilstrup D.M., Kurland L.T. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982, 97:672-680.
36. Gonzalez-Gay M.A., Martinez-Dubois C., Agudo M., Pompei O., Blanco R., Llorca J., et al. Giant cell arteritis: epidemiology, diagnosis, and management. Curr Rheumatol Rep 2010, 12:436-442.
37. Yates M., Loke Y.K., Watts R.A., MacGregor A.J. Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis. Clin Rheumatol 2014, 33:227-236.
38. Martínez-Taboada V.M., Rodríguez-Valverde V., Carreño L., López-Longo J., Figueroa M., Belzunegui J., et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008, 67:625-630.
39. Schafer V.S., Zwerina J. Biologic treatment of large-vessel vasculitides. Curr Opin Rheumatol 2012, 24:31-37.
40. Silva-Fernández L., Loza E., Martínez-Taboada V.M., Blanco R., Rúa-Figueroa I., Pego-Reigosa J.M., et al. Biological therapy for systemic vasculitis: A systematic review. Semin Arthritis Rheum 2014, 43:542-557.
41. Ortiz-Sanjuán F., Blanco R., Calvo-Rio V., et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol 2014, 66:1659-1665.
42. Prieto-González S., Depetris M., García-Martínez A., Espígol-Frigolé G., Tavera-Bahillo I., Corbera-Bellata M., et al. Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control study. Ann Rheum Dis 2014, 73:1388-1392.
43. Gonzalez-Gay M.A., Barros S., López-Díaz M.J., Garcia-Porrua C., Sanchez-Andrade A., Llorca J., et al. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine 2005, 84:269-276.
44. Gonzalez-Gay M.A. Giant cell arteritis and polymyalgia rheumatic: two different but often overlapping conditions. Semin Arthritis Rheum 2004, 33:289-293.
45. Gonzalez-Gay M.A., Agudo M., Martinez-Dubois C., Pompei O., Blanco R. Medical management of polymyalgia rheumatica. Expert Opin Pharmacother 2010, 11:1077-1087.
46. Mori S., Koga Y. Glucocorticoid-resistant polymyalgia rheumatic: pretreatment characteristics and tocilizumab therapy. Clin Rheumatol 2014, 10.1007/s10067-014-2650-y.
47. Al Rashidi A., Hegazi M.O., Mohammad S.A., Varghese A. Effective control of polymyalgia rheumatica with tocilizumab. J Clin Rheumatol 2013, 19:400-401.
48. Ashraf Fa Anjum S, Hussaini A., Fraser A. Refractory PMR with aortitis: life-saving treatment with anti-IL6 monoclonal antibody (tocilizumab) and surgical reconstruction of the ascending aorta. BMJ Case Rep 2013, 2013.
49. Macchioni P., Boiardi L., Catanoso M., et al. Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature. Semin Arthritis Rheum 2013, 43:113-118.
50. Unizony S.H., Dasgupta B., Fisheleva E., Pulsatelli L., Pipitone N., Meliconi R., et al. Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol 2013, 2013:912562.